
ADMA Biologics Faces Class Action Over Revenue Allegations
Investors who acquired ADMA Biologics stock between August 9, 2024, and March 25, 2026, are now represented in a newly filed securities class action. The lawsuit claims the biopharmaceutical firm misled shareholders by allegedly inflating revenue figures through channel stuffing and failing to disclose related-party transactions.














/bmi/media/post_banners/685374a708a95156958d6658a6e64c51d2d6e73262d48b69d1988c2ac58cb616.jpg)









